InvestSMART

Ceryvyn Therapeutics Limited (ASX: CYV) - Share Price

Current share price for CYV : $0.012 0.001 (7.69%)+

Ceryvyn Therapeutics Limited (CYV, formerly Opthea Limited), an ASX-listed company, is an ASX listed biopharmaceutical company which researches and develops novel therapeutic products based on targeting Vascular Endothelial Growth Factors (VEGF) C, D and R3. Since FY2014, the Company has been committed to the development of new therapies for the treatment of serious eye diseases that affect the back of the eye, or retina, and lead to vision loss. The Company's lead candidate was sozinibercept a VEGF C/D trap inhibitor being developed for use in conjunction with VEGF A inhibitors for the treatment of wet AMD and other retinal diseases.

CYV General Information +

ASX Code CYV
Website http://www.opthea.com
Industry/Sector Biotechnology
Market Cap ($M) 16
CYV Share Price $0.012
Day High $0.012
Day Low $0.012
Last Close $0.013
CYV Share Price Movement $0.00 ( 7.69% )
Prices as at 16:40, 20 Jul 2026
+Security prices are delayed by at least 20 minutes and are indicative only.

Ceryvyn Therapeutics Limited (CYV) Upcoming Dividends & Yields

Distribution Type Dividend Franking Ex-dividend date Payment date Current Price+ Price 7D Avg Dividend Yield

See all dividends from Ceryvyn Therapeutics Limited (CYV) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Ceryvyn Therapeutics Limited (CYV) Recent ASX Announcements

Company Sector Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
Ceryvyn Therapeutics Limited (CYV)
ORDINARY FULLY PAID
 Health Care $16 Update to Executive Chair Remuneration Arrangements 17 Jul 2026 2:47PM $0.013 $0.012 fallen by 7.69%
Ceryvyn Therapeutics Limited (CYV)
ORDINARY FULLY PAID
 Health Care $16 Notification of cessation of securities - CYV 13 Jul 2026 2:44PM $0.013 $0.012 fallen by 7.69%
Ceryvyn Therapeutics Limited (CYV)
ORDINARY FULLY PAID
 Health Care $16 Change of Company's Constitution 10 Jul 2026 1:06PM $0.012 $0.012 fallen by 0%

CYV Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2025A -$248.46 -$20.30 -61.10% 0.00 0.00 0.00% 0.0%
2024A -$332.49 -$52.10 23.60% 0.00 0.00 0.00% 0.0%
2023A -$214.96 -$42.20 26.70% 0.00 0.00 0.00% 0.0%

CYV Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2023 A 2024 A 2025 A 2023 A 2024 A 2025 A 2023 A 2024 A 2025 A
CSL Limited (CSL) $59,059M 0.1108 -0.1186 0.0168 13.2237 15.0035 14.7560 3.61% 2.96% 3.08%
Clinuvel Pharmaceuticals Limited (CUV) $500M 0.0287 0.0000 0.0000 13.8162 0.0000 0.0000 0.50% 0.00% 0.00%
Ceryvyn Therapeutics Limited (CYV) $18M -0.6106 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Mesoblast Limited (MSB) $3,164M 0.0301 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Telix Pharmaceuticals Limited (TLX) $5,066M -1.3893 0.0000 -0.1300 0.0000 273.0769 313.8947 0.00% 0.00% 0.00%

CYV Market Comparison

Earnings P/E Ratio P/B Ratio P/E Growth
Company 0.00 0.00 -0.05 0.00
Market 0.31 12.90 1.13 0.59
Sector 0.45 28.10 2.50 1.92

CYV Directors

Name Position Start Date
Dr Jeremy Levin Non-Executive Chairman, Non-Executive Director 12 Oct 2020
Mr Lawrence Bernard Gozlan Non-Executive Director 24 Jul 2020
Ms Katherine(Kathy) Ellen Danielle Connell Non-Executive Director 15 Nov 2024

Ceryvyn Therapeutics Limited (CYV) Changes in Directors' Interest & Trades

Date of change Director Buy/Sell Security Type Qty Trade Price Value
23 Jun 2026 LEVIN, Jeremy Buy Direct Shares 13,390,000 $0.014 $188,799.000
17 Jun 2026 GOZLAN, Lawrence Sell Indirect Shares 1,877,357 $0.015 $28,160.330
15 Jun 2026 CONNELL, Katherine(Kathy) Buy Indirect Shares 2,000,000 $0.015 $30,000.000

See all changes in directors' interest & trades for Ceryvyn Therapeutics Limited (CYV) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

CYV Management

Name Position
Judith Robertson Chief Commercial Officer
Tom Reilly Chief Financial Officer
Hamish George Chief Financial Officer,Joint Company Secretary
Parisa Zamir Chief Medical Officer
Megan Baldwin Founder, Chief Innovation Officer and Executive Director
Stephanie Vipond Joint Company Secretary

CYV Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Ceryvyn Therapeutics Limited (CYV). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding Name
319,779,459 (25.97%) Regal Funds Management Pty Limited
99,442,577 (8.08%) The Bank of New York Mellon Corporation

CYV Calendar of Events

Date Event
01 March 2027 Report (Interim)
14 September 2026 Report (Annual)
28 August 2026 Report (Prelim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.